Sanpras Healthcare Private Limited

Sanpras Healthcare Private Limited, established on November 9, 2009, is a privately held pharmaceutical company headquartered in Sinnar, Maharashtra, India. The company specializes in the formulation and development of finished pharmaceutical products, focusing on oral liquid formulations such as syrups, suspensions, and solutions. Its Corporate Identification Number (CIN) is U85100MH2009PTC196966, and it is registered under the Registrar of Companies, Mumbai.

The authorized capital of Sanpras Healthcare is ₹3.00 crore, with a paid-up capital of ₹2.60 crore. As of April 8, 2024, the company employed 56 professionals, including skilled pharmacists and quality control specialists. The leadership team comprises Directors Santosh Waman Mutkule, Ramesh Narandas Rughani, and Sunanda Vaman Mutkule.

Sanpras Healthcare operates a dedicated oral liquid manufacturing plant located in Musalgaon, Sinnar, Maharashtra. This facility is equipped to produce a wide range of oral liquid formulations, catering to both pediatric and adult patients. The plant adheres to Good Manufacturing Practices (GMP) guidelines, ensuring the production of high-quality and safe pharmaceutical products.

The company's leadership includes Directors Santosh Waman Mutkule, Ramesh Narandas Rughani, and Sunanda Vaman Mutkule. These individuals bring extensive experience in the pharmaceutical industry, contributing to the company's strategic direction and operational success.

Sanpras Healthcare's export portfolio, valued at $2.3 million USD across 125 shipments, includes products such as Lactulose, Ambroxol, Bromhexine, and Melatonin. The company's focus on finished pharmaceutical formulations positions it to meet the stringent regulatory requirements of markets like the United States, European Union, United Kingdom, Australia, and Japan. While specific regulatory approvals are not detailed, the company's adherence to GMP standards suggests a commitment to meeting international quality benchmarks.

Sanpras Healthcare's export activities indicate a presence in emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's adherence to WHO GMP guidelines enhances its potential for obtaining WHO prequalification, facilitating access to these markets. However, specific details regarding market penetration and prequalification status are not provided.

Sanpras Healthcare's export strategy demonstrates a diversified approach, with products spanning therapeutic categories such as Gastrointestinal (53.1%), Respiratory & OTC (40.3%), and Nutritional Supplements (6.6%). This diversification mitigates concentration risk and aligns with the company's strategic direction to serve a broad patient base.

Specific details regarding Sanpras Healthcare's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's adherence to GMP standards suggests a commitment to meeting international quality benchmarks, which is essential for FDA approvals.

Sanpras Healthcare's manufacturing facility adheres to WHO GMP guidelines, ensuring the production of high-quality pharmaceutical products. While specific certifications such as WHO prequalification or EU GMP certificates are not detailed, the company's commitment to quality suggests potential for obtaining these certifications.

Sanpras Healthcare holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), ensuring compliance with Indian regulatory standards. The company's adherence to GMP guidelines further supports its compliance with Indian regulatory requirements.

As of March 28, 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Sanpras Healthcare. The company's adherence to GMP standards and commitment to quality suggest a proactive approach to regulatory compliance.

Sanpras Healthcare operates in a competitive landscape with companies such as Zuventus HealthCare, Windlas Biotech, and Shenzhen Tsumura Medicine. While specific market share comparisons are not available, Sanpras Healthcare's diversified product portfolio and adherence to quality standards position it favorably in the market.

Sanpras Healthcare's focus on high-quality oral liquid formulations, adherence to GMP guidelines, and commitment to customer satisfaction distinguish it in the pharmaceutical industry. The company's dedicated manufacturing facility and experienced leadership team further enhance its competitive advantages.

Sanpras Healthcare's strategic direction emphasizes the production of high-quality, affordable pharmaceutical products across various therapeutic segments. The company's adherence to GMP standards and focus on customer satisfaction align with its mission to serve the healthcare sector both nationally and internationally.

Sanpras Healthcare's export volume and consistency, along with its adherence to GMP standards, indicate a reliable track record as a pharmaceutical supplier. The company's commitment to quality and customer satisfaction further enhance its reliability indicators.

Importers should verify certifications such as WHO GMP, EU GMP, and ISO standards to ensure product quality and compliance. Verification can be conducted through official regulatory bodies or by requesting certification documents directly from the supplier.

• Verify manufacturing licenses and certifications.
• Assess product quality through sample testing.
• Review financial stability and creditworthiness.
• Evaluate compliance with international regulatory standards.
• Check for any history of regulatory violations or warnings.

By conducting thorough due diligence, importers can ensure a reliable and compliant partnership with Sanpras Healthcare.